MoonLake Immunotherapeutics (NASDAQ:MLTX) Financings

MoonLake Immunotherapeutics

Financings

RaiseDate
Public offering of class A ordinary shares and pre-funded warrants
Made bigger: about US$200M · US$20 a share · Leerink Partners +5
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital (co-lead), H.C. Wainwright & Co., Clear Street
Use of proceeds: Research, development, pre-commercialization and commercialization of sonelokimab, if approved, and general corporate purposes
Jun 24, 2026
Public offering of class A ordinary shares
Announced: about US$75M · US$10.5 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Use of proceeds: To fund research and development of sonelokimab and for general corporate purposes
Nov 5, 2025

Read by 6ix AI from the company's releases